Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.
IVIG is the definitive therapy for primary immunodeficiency diseases associated with hypogammaglobulinemia or specific antibody deficiencies. Administration of IVIG is relatively safe, but occasional adverse reactions are usually self-limited and generally are not an indication for stopping therapy. Home administration of IVIG has found increasing favor among treating physicians and their patients.
Schwartz
S A
SA
Department of Pediatrics, University of Michigan, Ann Arbor 48109-2029.
D000361:Agammaglobulinemia / Q000235:genetics / Q000628:therapy; D005260:Female; D006801:Humans; D017098:IgA Deficiency; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D007223:Infant; D008297:Male
D016756:Immunoglobulins, Intravenous